News
Modella AI has signed a multi-year agreement with AstraZeneca for expediting AI-driven oncology clinical development.
Merck and AstraZeneca have seen their share prices surge after Bristol-Myers Squibb suffered a major setback with Opdivo in non-small cell lung cancer (NSCLC). BMS announced on Friday that Opdivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback